| 21838707 |
Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684
Schönherr, C,
Eriksson, T,
Christensen, J,
Palmer, RH,
Hallberg, B,
Ruuth, K,
Yamazaki, Y
|
Biochem J |
2011 |
| 11110708 |
Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway
Ouyang, T,
Morris, SW,
Bai, RY,
Duyster, J,
Miething, C,
Peschel, C
|
Blood |
2000 |
| 23104988 |
Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma
Ohira, M,
Marra, MA,
Palmer, RH,
Nakagawara, A,
Attiyeh, EF,
Schönherr, C,
Kogner, P,
Sandström, PE,
Morozova, O,
Martinsson, T,
Maris, J,
Hallberg, B,
Ruuth, K,
Yamazaki, Y,
Chand, D
|
Dis Model Mech |
2013 |
| 21494621 |
Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas
Reiter, A,
Siebert, R,
Melnick, A,
Pott, C,
Damm-Welk, C,
Yang, SN,
Klapper, W,
Harder, L,
Vater, I,
Woessmann, W,
Cerchietti, L
|
PLoS One |
2011 |
| 21656749 |
A novel KIF5B-ALK variant in nonsmall cell lung cancer
Leung, EL,
Tin, VP,
Wong, MP,
Au, JS,
Cheng, LC,
Sihoe, AD,
Wong, DW,
Chung, LP,
Wong, SK
|
Cancer |
2011 |
| 18923525 |
Activating mutations in ALK provide a therapeutic target in neuroblastoma
Zozulya, S,
George, RE,
Gilliland, DG,
Morris, SW,
Luther, W,
London, WB,
Hanna, M,
Meyerson, M,
McGrady, P,
Sanda, T,
Gregor, VE,
Look, AT,
Zhang, J,
Fröhling, S,
Ahn, Y,
Diller, L,
Webb, TR,
Zhou, W,
Greulich, H,
Gray, NS,
Xue, L
|
Nature |
2008 |
| 22249260 |
Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma
Hayashi, Y,
Chen, Y,
Igarashi, T,
Hiwatari, M,
Takita, J,
Ogawa, S,
Okubo, J,
Nishimura, R,
Sanada, M,
Kato, M,
Oki, K
|
Oncogene |
2012 |
| 22570254 |
Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer
Haack, H,
Ren, JM,
Gu, TL,
Zhu, X,
Innocenti, G,
Crosby, K,
Tan, ZP,
Moritz, A,
Yang, YF,
Ren, H,
Rush, J,
Beausoleil, S,
Comb, MJ,
Zhang, Y,
Zhou, XM
|
Cancer Res |
2012 |
| 23139213 |
Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastoma
Louis-Brennetot, C,
Schleiermacher, G,
Loew, D,
Pierron, G,
Ferrand, S,
Daveau, R,
Cappo, J,
Vigny, M,
Jouannet, S,
Delattre, O,
Dingli, F,
Lombard, B,
Boeva, V,
Cazes, A,
Janoueix-Lerosey, I,
Combaret, V,
Mazot, P,
Barillot, E
|
Cancer Res |
2013 |
| 21415216 |
Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer
Jänne, PA,
Takezawa, K,
Nishio, K,
Nakagawa, K,
Okamoto, I
|
Clin. Cancer Res. |
2011 |
| 18594010 |
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
Koivunen, JP,
Murphy, C,
Thomas, R,
Zejnullahu, K,
Jänne, PA,
Holmes, AJ,
Ducko, C,
Sugarbaker, DJ,
Lifshits, E,
Choi, HG,
Chiang, D,
Meyerson, M,
Engelman, JA,
Lee, C,
Lindeman, N,
Lee, J,
Richards, WG,
Marcoux, JP,
Kim, J,
Gray, NS,
Mermel, C
|
Clin Cancer Res |
2008 |
| 18923524 |
Oncogenic mutations of ALK kinase in neuroblastoma
Ohira, M,
Kikuchi, A,
Soda, M,
Kato, M,
Choi, YL,
Nakagawara, A,
Hayashi, Y,
Wang, L,
Ogawa, S,
Chen, Y,
Sanada, M,
Takita, J,
Mano, H,
Igarashi, T
|
Nature |
2008 |
